EMA recommends approval of two improved COVID-19 vaccines
- FDA Approved a Neurostimulation Therapy for Major Depressive Disorder
- What is the research progress of immunotherapy for Alzheimer’s disease?
- Protein linked to significantly increased risk of Alzheimer’s disease
- How much do you know about monkeypox?
- COVID-19 linked to dramatic increase in type 1 diabetes in children: up to 72%
- New therapy may conquer cancer with herpes virus
EMA recommends approval of two improved COVID-19 vaccines
- New breakthrough in CAR-T cell therapy: Lupus erythematosus patients achieved treatment-free remission for up to 17 months
- Is the new COVID Omicron variant BA.4.6 more contagious?
- How long can the patient live after heart stent surgery?
- First time: Systemic multi-organ recovery after death
- Where do the bacteria in the human gut come from?
The European Medicines Agency (EMA) recommends approval of two improved COVID-19 vaccines.
On September 1, the European Medicines Agency recommended the approval of two improved vaccines against the mutated new coronavirus Omicron strain BA.1, saying that it can be used as a booster shot for people aged 12 and over who have completed the initial vaccination.
The European Medicines Agency said that the two improved vaccines are based on the Comirnaty vaccine produced by the American Pfizer Pharmaceutical Co., Ltd. and the German biotech company and the Spikevax vaccine produced by the American Moderna company.
In addition to the new coronavirus strain, it can also act on the spike protein of the mutant new coronavirus Omicron strain BA.1.
Studies have shown that vaccination with an improved version of the vaccine 3 months after the initial vaccination can stimulate a strong immune response against the BA.
On the one hand, it is more effective than the initial vaccine. Side effects of the improved vaccine are comparable to those of the original vaccine and are usually mild and short-lived.
The agency said marketing recommendations for the two improved vaccines would be submitted to the European Commission for final approval.
The European Medicines Agency explained that with the development of the COVID-19 epidemic, the EU’s strategy is to provide a series of improved vaccines against multiple new coronavirus mutant strains, so that member states can have multiple options when formulating vaccination strategies.
Since it is impossible to predict how the virus will mutate in the future and which mutated strains will be prevalent this winter, this strategy is critical to the EU’s overall strategy to deal with the COVID-19 epidemic.
The European Medicines Agency also stated that improved vaccines against Omicron subtype strains such as BA.4 and BA.5 are currently being tested, and some will be submitted soon. If approved, it will further expand the available vaccine resources.
The European Medicines Agency said that the current Comirnaty and Spikevax vaccines remain effective in preventing severe illness, hospitalization and death related to the new coronavirus and will continue to be used for vaccinations in the EU, especially as initial vaccinations.
EMA recommends approval of two improved COVID-19 vaccines
(source:internet, reference only)
Disclaimer of medicaltrend.org
